Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
Novo Nordisk
Biotech
Novo plots ph. 3 trials for next-gen obesity asset amycretin
The Danish pharma is moving forward with both subcutaneous and oral versions of amycretin, a GLP-1 and amylin receptor agonist.
Gabrielle Masson
Jun 13, 2025 10:35am
'The opportunities are immense': Novo to use supercomputer
Jun 11, 2025 8:35am
Novo Nordisk inks $812M Deep Apple deal to pursue obesity target
Jun 11, 2025 7:00am
Weight of market pressures pushes Novo CEO out—Chutes & Ladders
May 23, 2025 8:30am
Fierce Pharma
Novo's longtime CEO Lars Fruergaard Jørgensen to step down
May 16, 2025 9:41am
Pathos AI's $365M series D to fund trial of Novo tumor drug
May 15, 2025 10:20am
